Cagrilintide Dosage Chart: 45 Trials, 22 in Phase 3, 1 Sponsor
Cagrilintide has a large late-stage programme and no approval. What its trial quantities are, why they are not authorised doses, and why the combination partner matters.
MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
A cagrilintide dosage chart sits in an unusual position for this site. The numbers exist, they were measured in humans, and they were published. What they are not is authorised.
Three counts frame it: 45 registered studies, 22 of them Phase 3, and 1 sponsor across every single entry.
The programme, counted
ClinicalTrials.gov returns roughly 45 studies under the name, and the phase distribution is that of a genuine development programme rather than a research chemical.
| Phase | Studies |
|---|---|
| Phase 3 | 22 |
| Phase 1 | 17 |
| Phase 2 | 6 |
About 25 are completed, ten recruiting and seven active but not recruiting. Novo Nordisk is lead sponsor on all of them, with no academic or independent entries anywhere in the registry.
Why the arithmetic is better anchored here
Most pages on this site perform exact arithmetic on an unanchored target: labelled mass over diluent volume is precise, but the quantity being aimed at comes from a rodent study that does not convert.
Cagrilintide is different in one respect that matters. Its quantities were established in humans, in protocols with prespecified endpoints, through dose-finding that actually happened. There is a real number to divide into rather than a reconstruction.
What has not happened is authorisation. No regulator has approved the compound, so no labelled quantity exists and nobody outside the sponsor is accountable for one. Trial figure and authorised dose are different objects, and only the second carries an institution behind it.
The combination is part of the figure
This is the detail most charts drop, and it changes what a number means.
The registered programme studies cagrilintide alongside semaglutide, as CagriSema. Searches frequently ask about cagrilintide with tirzepatide instead. That combination is not what these trials examined, and the partner drug is not interchangeable: mechanism, half-life and titration schedule all differ.
So a figure carries three attachments, not one: the quantity, the partner it was studied with, and the schedule it sat in. A cagrilintide dosage chart that reports all three is doing the job. One that reports only the first has dropped the two that determine whether it transfers.
Frequently Asked Questions
Is cagrilintide approved anywhere?expand_more
No. Despite roughly 45 registered studies including 22 in Phase 3, no regulator has approved it, so no label and no authorised quantity exist.
Who sponsors the studies?expand_more
Novo Nordisk is lead sponsor on every registered entry. There is no independent or academic replication in the registry.
Do the trial figures apply to a tirzepatide combination?expand_more
No. The registered work pairs cagrilintide with semaglutide. A different partner drug means a different mechanism, half-life and titration, so figures do not carry across.
Is a trial quantity the same as a dose?expand_more
No. A trial quantity is what a protocol administered under defined conditions. A dose is an authorised quantity a regulator approved, and that step has not happened here.
How complete is the programme?expand_more
Around 25 of the 45 studies are recorded as completed, with roughly ten recruiting and seven active but not recruiting.
References & Citations
- [1]
ClinicalTrials.gov. Studies registered under the term cagrilintide: approximately 45 records, 22 Phase 3, 17 Phase 1, 6 Phase 2; Novo Nordisk lead sponsor throughout.View source →